Key Highlights
- Novo Nordisk shares surged more than 6% following the FDA’s proposal to eliminate semaglutide, tirzepatide, and liraglutide from the 503B bulks compounding registry
- Federal regulators stated outsourcing facilities have no medical justification to compound these medications
- Public feedback window remains open through June 29, 2026, ahead of the agency’s final ruling
- NVO reached its strongest trading position in over 60 days, leading Copenhagen’s stock market on Thursday
- Despite the rally, shares remain underwater by more than 16% for the current year
Shares of Novo Nordisk experienced a sharp rally exceeding 6% Thursday following the Food and Drug Administration’s proposal to curtail compounding activities for popular weight-loss medications—a development that stands to significantly advantage the Copenhagen-based pharmaceutical manufacturer.
The regulatory agency put forward a plan to strike semaglutide, tirzepatide, and liraglutide from the 503B bulks registry. According to the FDA, there exists no medical rationale for outsourcing operations to produce compounded versions of these treatments.
The pharmaceutical company’s stock climbed to its strongest level in over 60 days during Thursday’s session and emerged as the leading gainer on Copenhagen’s exchange.
NVO was changing hands near $42.38 during recent trading, comfortably exceeding its 20-day moving average of $39.03 and its 50-day moving average of $38.87.
Yet even with Thursday’s impressive advance, the stock continues trading beneath its 200-day moving average of $50.32 and carries a year-to-date decline exceeding 16%.
The regulatory body has initiated a public consultation window extending through June 29, 2026, before finalizing any determination on the proposed restrictions.
Challenges Facing the Danish Drugmaker
Novo Nordisk has encountered multiple obstacles in recent months. Canadian health authorities greenlit the nation’s first generic alternative to Ozempic, introducing fresh competitive pressure in a significant market.
As a countermeasure, management instituted a stock repurchase initiative. The company has bought back approximately 13.4 million B-shares valued at 3.44 billion Danish kroner since February 2026, representing part of a broader 15 billion kroner, 12-month program.
Regarding its development pipeline, the pharmaceutical firm has initiated a Phase 3 clinical study for a knee osteoarthritis therapy and secured FDA fast-track status for a cardiovascular medication.
First-quarter 2026 financial results are slated for release on May 6.
Technical Analysis Perspective
Near-term price action appears favorable. The MACD indicator is displaying a buy signal while the RSI registers 54.73, reflecting moderately bullish sentiment.
Nevertheless, the ADX measurement of 17.26 indicates the prevailing trend lacks substantial strength. The Stochastic RSI is generating a sell signal, highlighting potentially overbought territory.
Anton Kharitonov from Traders Union highlighted the delicate technical landscape, noting that weak momentum readings and overbought conditions indicate purchasing pressure may fade rapidly. He identified the generic Ozempic threat in Canada as an additional risk factor.
Viktor Karapetjanc, also affiliated with Traders Union, maintains a more optimistic outlook. He views the share repurchase initiative and robust clinical development program as foundations for sustained value, characterizing the recent decline as a possible springboard.
Market analyst Jainam Mehta identifies a tactical trading zone between $40.78 and $43.23 as the critical area to monitor. He emphasized that a definitive breach above or below these thresholds would be necessary to alter the short-term risk assessment.
The stock commenced Thursday’s session with a gap higher of approximately $0.37 and accumulated gains of $1.94, representing a 4.80% intraday advance. Intraday price fluctuation measured 2.47%.
